Unknown

Dataset Information

0

Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen.


ABSTRACT: BACKGROUND:Evidence that simian virus 40 (SV40) is associated with human mesotheliomas, osteosarcomas, and brain tumors suggests that a recombinant vaccine directed against lethal cancers expressing SV40 T antigen (Tag) could have clinical utility. To address this potential need, we designed a novel vaccinia virus construct that encodes an SV40 Tag in which oncogenic domains were excluded and immunogenic domains were preserved. We named this recombinant construct vaccinia-encoding safety-modified SV40 Tag (vac-mTag). METHODS:Purified vac-mTag was characterized by DNA sequencing, reverse transcription-coupled polymerase chain reaction, western blot analysis, and immunocytochemical techniques. Induction of Tag-specific immunity was examined by cytolytic T-cell assays, and the efficacy of vac-mTag in protecting animals against Tag-expressing tumors and in treating pre-established microscopic tumors was evaluated in vac-mTag-immunized BALB/c mice. RESULTS:The immune response elicited by vac-mTag in C57BL/6 and BALB/c mice included an SV40 Tag-specific cytolytic T-lymphocyte activity against syngeneic (identical genetic background) SV40 Tag-expressing tumor targets. Immunization of mice with a single dose of vac-mTag resulted in potent protection against subsequent challenge with a lethal mouse cancer expressing SV40 Tag. In addition, single-dose vac-mTag immunization coadministered with interleukin 2 produced a possible therapeutic effect against a preadministered microscopic (but lethal) burden of Tag-expressing tumor cells in vivo. CONCLUSION:vac-mTag induces an effective immune response in mice that is specific for a tumor-associated antigen. This response protects against a lethal tumor challenge and results in a possible therapeutic effect against Tag-expressing tumors in vivo. Thus, vac-mTag provides a new avenue for the development of therapies for human cancers thought to be associated with SV40.

SUBMITTER: Xie YC 

PROVIDER: S-EPMC2249695 | biostudies-literature | 1999 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen.

Xie Y C YC   Hwang C C   Overwijk W W   Zeng Z Z   Eng M H MH   Mulé J J JJ   Imperiale M J MJ   Restifo N P NP   Sanda M G MG  

Journal of the National Cancer Institute 19990101 2


<h4>Background</h4>Evidence that simian virus 40 (SV40) is associated with human mesotheliomas, osteosarcomas, and brain tumors suggests that a recombinant vaccine directed against lethal cancers expressing SV40 T antigen (Tag) could have clinical utility. To address this potential need, we designed a novel vaccinia virus construct that encodes an SV40 Tag in which oncogenic domains were excluded and immunogenic domains were preserved. We named this recombinant construct vaccinia-encoding safety  ...[more]

Similar Datasets

| S-EPMC2168793 | biostudies-literature
| S-EPMC2939315 | biostudies-literature
| S-EPMC110153 | biostudies-literature
| S-EPMC327122 | biostudies-literature
| S-EPMC1472039 | biostudies-literature
| S-EPMC4078001 | biostudies-literature
| S-EPMC1892755 | biostudies-literature
2009-07-18 | GSE17178 | GEO
| S-EPMC2224577 | biostudies-literature
| S-EPMC3948260 | biostudies-literature